DSIP (Delta Sleep-Inducing Peptide): Complete Research Guide 2026 | Peptadex

What Is DSIP?

DSIP (Delta Sleep-Inducing Peptide) is a neuropeptide consisting of nine amino acids (Trp-Ala-Gly-Gly-Asp-Ala-Ser-Gly-Glu) that was first isolated from rabbit cerebrospinal fluid in 1974 by Swiss researchers Marcel Monnier and Luzius Schoenenberger. Its name reflects the original hypothesis that it could induce delta (slow-wave) sleep states when administered to research animals.

DSIP is also known as emideltide and is naturally produced in the hypothalamus and pituitary gland. It is found in peripheral blood and various tissues, suggesting roles beyond sleep regulation. As of 2026, it is under active regulatory review by the FDA and scheduled for an advisory panel on July 24, 2026.

Key Takeaways

• DSIP is a naturally occurring 9-amino-acid neuropeptide first isolated in 1974
• It is on the FDA's Pharmacy Compounding Advisory Committee (PCAC) review agenda for July 24, 2026
• Preclinical research suggests roles in sleep modulation, stress response, and antioxidant activity
• No large-scale human clinical trials have been published as of 2026
• Its removal from FDA Category 2 is pending PCAC review and 503A bulk drug listing

Mechanism of Action

DSIP does not have a single well-characterized receptor. Research suggests it may interact with multiple receptor systems, including opioid, serotonin, and GABA-ergic pathways. This polymodal activity may explain why its effects in animal studies span across sleep, stress, pain, and oxidative stress domains.

Sleep Modulation

Early research in cats and rabbits showed that intraventricular injection of DSIP increased non-REM (slow-wave) sleep duration. However, subsequent studies in humans and other mammalian models produced inconsistent results, and the direct "sleep-inducing" classification has been questioned in later literature.

Stress Response

Animal studies have suggested that DSIP may modulate the hypothalamic-pituitary-adrenal (HPA) axis, potentially reducing excessive glucocorticoid release under stress conditions. This has led to research interest in its role in stress-related pathologies.

Antioxidant Properties

Some preclinical data suggests DSIP may have antioxidant activity, reducing oxidative stress markers in aged or stressed animal models. This has drawn interest in longevity and anti-aging research circles.

What Does the Research Actually Show?

The DSIP research literature is smaller than that of better-known peptides like BPC-157 or Epitalon. Most studies are from the 1980s and 1990s, are small-scale, and many were conducted in Soviet and Eastern European research contexts with limited reproducibility in Western peer review.

A key limitation is that DSIP's blood-brain barrier permeability is debated. If the peptide cannot readily cross the BBB when administered peripherally, many of its proposed central nervous system effects may not be reproducible via subcutaneous or intravenous routes used in self-research contexts.

DSIP and the FDA 2026 Regulatory Landscape

DSIP (emideltide) was previously on the FDA's Category 2 list, which restricted its use in compounded medications due to safety concerns. Under the 2026 regulatory changes announced by the Department of Health and Human Services, 12 peptides were removed from Category 2 effective April 22, 2026.

DSIP is scheduled for Pharmacy Compounding Advisory Committee (PCAC) review on July 24, 2026 — the same session as Epitalon and Semax. This review will determine whether DSIP can be added to the 503A bulk drug substances list, which would allow licensed compounding pharmacies to prepare it with a valid physician prescription.

Removal from Category 2 does not constitute FDA approval and does not mean DSIP is legal to compound without completing the full PCAC process. The distinction is important for anyone tracking the regulatory timeline.

How Does DSIP Compare to Other Sleep Peptides?

Researchers interested in sleep-related peptides often compare DSIP with DSIP, VIP (Vasoactive Intestinal Peptide), and Selank, which has documented anxiolytic effects in Russian clinical research. See our peptide comparison tool for a side-by-side breakdown.

Dosing in Research Contexts

In the limited human studies published, DSIP has been studied at doses ranging from 20 to 30 nanomoles per kilogram administered intravenously. Some animal studies used subcutaneous protocols. Due to the scarcity of human data, no established dosing protocol exists outside of supervised research settings.

Side Effects and Safety Considerations

Human safety data for DSIP is extremely limited. Animal toxicology studies have generally not identified major acute toxicity at research doses. However, the absence of documented adverse effects in sparse research literature should not be interpreted as a clean safety profile. Peptides with limited human data carry inherent uncertainty.

Current Status Summary

DSIP remains one of the more understudied peptides in the compounding discussion. Its inclusion in the July 24 PCAC review alongside better-known peptides like Epitalon suggests regulatory interest. However, the evidence base supporting its clinical utility is substantially thinner than for peptides with more extensive research programs.

Researchers and clinicians interested in the sleep peptide space should watch the PCAC outcomes in July 2026, which will shape the legal compounding landscape for DSIP through the remainder of the year.

Disclaimer: This article is for educational purposes only. DSIP is not FDA-approved for any medical use. Nothing in this article constitutes medical advice. Always consult a qualified healthcare professional before making any decisions about your health or any compounds discussed here.